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http://dxObjective: This study aimed to compare malignant behavior and prognosis between solid tumors and mixed
tumors with a ground-glass opacity component on high-resolution computed tomography.
Methods:Weexamined 436of 502 consecutive patientswith clinical stage IAadenocarcinomawhohad undergone
preoperative high-resolution computed tomography and F-18-fluorodeoxyglucose positron emission tomography/
computed tomography; 66 patients with tumors with pure ground-glass opacity components were excluded. Tumor
type (solid, n ¼ 137; mixed, n ¼ 299) and surgical results were analyzed for all patients and their matched pairs.
Results: In all patients, solid tumors showed a significantly greater association (P<.001) with lymphatic, vas-
cular, and pleural invasion and lymph node metastasis compared with mixed tumors. The disease-free survival
was also worse in patients with solid tumors (P¼ .0006). Analysis of 97 pairs matched for solid component size
confirmed that solid tumors were significantly associated with lymphatic, vascular, and pleural invasion
(P ¼ .008, P ¼ .029, P ¼ .003, respectively) and poor prognosis. When maximum standardized uptake value
and solid component size were matched (n ¼ 79), the differences in pathologic prognostic parameters and
disease-free survivals between patients with solid and mixed tumors disappeared.
Conclusions: Solid tumors exhibit more malignant behavior and have a poorer prognosis compared with mixed
tumors, even when the solid component size is the same in both tumor types. However, differences in malignant
behavior can be identified using maximum standardized uptake values determined by F-18-fluorodeoxyglucose
positron emission tomography/computed tomography. (J Thorac Cardiovasc Surg 2013;146:17-23)Earn CME credits at
http://cme.ctsnetjournals.org
The recent development of high-resolution computed
tomography (HRCT) and low-dose computed tomography
(CT) screening has improved the detection of small lung
cancers, especially lung adenocarcinomas.1-3 These often
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The Journal of Thoracic and Cglass opacity (GGO) on HRCT and is closely associated
with bronchioloalveolar carcinoma.4,5 We have previously
reported the benefits of comparing solid component size
(the maximum dimension of the solid component
excluding GGO) on HRCT with whole tumor size for
predicting the pathologic invasiveness of tumors or the
prognosis of clinical stage IA lung adenocarcinomas.6 It
remains unclear whether GGO-containing tumors have
the same malignant behavior and prognosis as pure solid
tumors after matching for solid component size.
Whether or not differences exist inmalignant behavior be-
tween pure solid tumors andmixed tumors with aGGO com-
ponent on HRCT remains controversial. Therefore, we used
HRCT to compare malignant behavior, including lymphatic,
vascular, and pleural invasion, and prognosis between solid
tumors and mixed tumors having a GGO component in
patients with clinical stage IA lung adenocarcinoma.PATIENTS AND METHODS
Between August 1, 2005, and December 31, 2009, we enrolled 502
patients with clinical T1N0M0 stage IA lung adenocarcinoma who were
admitted to 1 of the following 4 institutions: Hiroshima University, Kana-
gawa Cancer Center, Cancer Institute Hospital, and Hyogo Cancer Center.
HRCT and F-18-fluorodeoxyglucose positron emission tomography/CTardiovascular Surgery c Volume 146, Number 1 17
Abbreviations and Acronyms
CT ¼ computed tomography
DFS ¼ disease-free survival
FDG-
PET
¼ F-18-fluorodeoxyglucose positron
emission tomography
FOV ¼ field of view
GGO ¼ ground-glass opacity
HRCT ¼ high-resolution computed tomography
SUV ¼ standardized uptake value
SUVmax ¼ maximum standardized uptake value
General Thoracic Surgery Tsutani et al
G
T
S(FDG-PET/CT) followed by curative R0 resection were performed in all
patients, who were staged according to the seventh edition of the TNM
classification of malignant tumors.7 Mediastinoscopy and endobronchial
ultrasonography were not routinely performed because HRCT revealed
no swelling of mediastinal or hilar lymph nodes and FDG-PET showed
no accumulation in these lymph nodes in all patients. Sublobar resections
(segmentectomy or wedge resection) were performed if the tumor mainly
comprised a GGO component or had no lymph node metastasis on intrao-
perative assessment. Tumors with pure GGO were excluded from the anal-
yses because they are noninvasive and have an extremely good
prognosis.8,9 We obtained appropriate approval for this multicenter study
from the institutional review board of each institution, which waived the
requirement for informed consent from individual patients because this
was a retrospective review of medical records from a prospective database.
High-Resolution Computed Tomography
Chest images were obtained using 16-row multidetector CT indepen-
dently of subsequent FDG-PET/CT examinations. High-resolution images
of the tumors were acquired using the following parameters: 120 kVp; 200
mA; section thickness, 1 to 2 mm; pixel resolution, 512 3 512; scanning
time, 0.5 to 1 seconds; a high spatial reconstruction algorithm with
a 20-cm field of view (FOV); and mediastinal (level, 40 HU; width, 400
HU) and lung (level, 600 HU; width, 1600 HU) window settings. GGO
was defined as a misty increase in lung attenuation that did not obscure
underlying vascular markings. We defined solid component size as the
maximum dimension of the solid component in the lung windows after
excluding the GGO component.6 Solid tumors were defined as pure solid
tumors without a GGO component, whereas mixed tumors were defined
as tumors with a GGO component regardless of the GGO proportion.
F-18-Fluorodeoxyglucose Positron Emission
Tomography/Computed Tomography
Patients were instructed to fast for more than 4 hours before intravenous
injection of 74 to 370MBq of FDG. After injection, they were instructed to
relax for at least 1 hour before FDG-PET/CT scanning. Blood glucose was
calculated before tracer injection to confirm a level of less than 150
mg/dL.10 Patients with blood glucose values 150 mg/dL or greater were
excluded from PET/CT image acquisition. Images were obtained using
Discovery ST (GE Healthcare, Little Chalfont, UK), Aquiduo (Toshiba
Medical Systems Corporation, Tochigi, Japan), or Biograph Sensation16
(Siemens Healthcare, Erlangen, Germany) integrated PET/CT scanners.
Low-dose, unenhanced CT images of 2- to 4-mm section thickness for
attenuation correction and localization of lesions identified by PET were
obtained from the head to the pelvic floor of each patient using a standard
protocol. Immediately after CT, PET covered the identical axial FOV for 2
to 4 minutes per table position depending on the condition of the patient
and scanner performance. All PET images with a 50-cm FOV were recon-
structed using an iterative algorithm with CT-derived attenuation18 The Journal of Thoracic and Cardiovascular Surgecorrection. Variations in standardized uptake values (SUVs) among institu-
tions were minimized using an anthropomorphic body phantom. A calibra-
tion factor was obtained by dividing the actual SUV by the gauged mean
SUV in the phantom background to decrease interinstitutional SUV incon-
sistencies; the final SUV used is referred to as the revised maximum SUV
(SUVmax).11,12 Adjustment of interinstitutional variability in SUV
narrowed the range from 0.89 to 1.24 to 0.97 to 1.18 when the SUVmax
ratio was expressed as the SUVmax reported by each institute relative to
the SUVmax reported by the control institute.
Follow-up Evaluation
All patients who underwent lung resection were followed up from the
day of surgery. Postoperative follow-up procedures, including physical
examination and chest roentgenography every 3 months and chest and
abdominal CT examinations every 6 months, were performed for the first
2 years. Thereafter, physical examination and chest roentgenography
were performed every 6 months, whereas chest CT examination was per-
formed every year. Recurrence was determined by radiographic features
or histologic evidence.
Statistical Analysis
Data are presented as numbers (%) or mean standard deviation unless
otherwise stated. Frequencies were compared using the chi-square test for
categoric variables, and the Fisher exact test was applied to small samples
in all cohort patients. McNemar tests were used for analyses of matched-
pair patients. Mann–Whitney U tests and t tests were used to compare
continuous variables in all cohort patients. Wilcoxon tests were used for
analyses of matched-pair patients. Disease-free survival (DFS) was defined
as the time from the date of surgery until the first event (relapse or death
from any cause) or last follow-up. The duration of DFS was analyzed using
the Kaplan–Meiermethod. Differences in DFSwere assessed using the log-
rank test. We applied matching to balance the assignment of the included
patients and correct for tumor type (solid or mixed), which confounded sur-
vival. The variables were solid component size or SUVmax. Solid and
mixed tumor pairs with an equivalent solid component size or SUVmax
were selected by a 1-to-1 match. All 436 patients were pooled and sorted
in ascending order according to their solid component size or SUVmax.
The selection process began from the first 2 cases with the lowest solid
component size or SUVmax. If 1 case exhibited a solid tumor and the other
case exhibited a mixed tumor, both were selected as a matched pair. If this
was not the case, then 4 cases were included. In the same way, solid and
mixed tumors were matched by their solid component size or SUVmax
in 1:1, 2:2, 3:3, or 4:4 blocks. A patient who did not have a suitable match
within the acceptable rank range was excluded from further analysis, and
the matching process moved down the sort list until all possible matched
pairs were included. The selected patients formed well-matched 1:1 pairs
in both groups. Data were analyzed using the Statistical Package for the
Social Sciences (v 10.5; SPSS Inc, Chicago, Ill).RESULTS
Of the 502 patients, 66 who had tumors with pure GGO
components were excluded; the remaining 436 patients
were included in this analysis. Of the 436 study patients,
137 had solid tumors and 299 had mixed tumors. The
mean follow-up period after surgery was 20.2  12.5
months, during which the disease recurred in 29 patients
(6.7%). The mean follow-up period was similar for solid
and mixed tumors (21.4  12.8 months and 19.7  12.4
months, respectively, P ¼ .235). Of the 29 cases of recur-
rence, 9 (2.1%) were local (including mediastinal lymph
node metastasis), 3 (0.7%) were local and distant, and 17ry c July 2013
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S(3.9%) were distant. Age, sex, and whole tumor size on
HRCT were not significantly different between patients
with solid and mixed tumors. Solid tumors were signifi-
cantly correlated with a large solid component size,
a high SUVmax, and the presence of lymphatic, vascular,
and pleural invasion and lymph node metastasis
(P < .001, P < .001, P < .001, P < .001, P < .001,
P ¼ .001, respectively; Table 1).
Local recurrence occurred in 5 patients (3.6%) with solid
tumors (1 involving the bronchial stump and 4 involving the
mediastinal lymph nodes) and 4 patients (1.3%) with mixed
tumors (1 involving the residual lung after segmentectomy
and 3 involving the mediastinal lymph nodes). A significant
difference in DFS was identified between patients with
solid tumors (n ¼ 137; 2-year DFS, 83.1%) and those
with mixed tumors (n ¼ 299; 2-year DFS, 94.2%;
P ¼ .0006; Figure 1, A).
After matching for solid component size, there were 97
well-matched solid and mixed tumor pairs. Significant dif-
ferences were identified in whole tumor size, SUVmax, and
lymphatic, vascular, and pleural invasion between the 2 tu-
mor types (P<.001, P<.001, P¼ .008, P¼ .029, P¼ .003,
respectively, Table 2). Solid tumors were significantly cor-
related with a small whole tumor size, a high SUVmax, and
the presence of pathologic invasiveness.
Furthermore, a difference in DFS was identified between
patients with solid tumors (n¼ 97; 2-year DFS, 83.5%) and
TABLE 1. Comparison of solid and mixed tumor characteristics in all
cohort patients
Solid tumors
(n ¼ 137)
Mixed tumors
(n ¼ 299) P
Age (y) 65.5  10.5 65.7  8.8 .85
Sex .12
Male 71 (51.8%) 130 (43.5%)
Female 66 (48.2%) 169 (56.5%)
Whole tumor size (cm) 2.1  0.6 2.0  0.6 .69
Solid component size (cm) 2.1  0.6 1.1  0.7 <.001
SUVmax 4.9  3.3 2.6  2.9 <.001
Lymphatic invasion <.001
Negative 89 (65.0%) 270 (90.3%)
Positive 48 (35.0%) 29 (9.7%)
Vascular invasion <.001
Negative 79 (57.7%) 264 (88.3%)
Positive 58 (42.3%) 35 (11.7%)
Pleural invasion <.001
Negative 100 (73.0%) 278 (93.0%)
Positive 37 (27.0%) 21 (7.0%)
Lymph node metastasis <.001
Negative 114 (83.2%) 284 (95.0%)
Positive 23 (16.8%) 15 (5.0%)
Procedure .001
Lobectomy 111 (81.0%) 190 (63.5%)
Segmentectomy 9 (6.6%) 48 (16.1%)
Wedge resection 17 (12.4%) 61 (20.4%)
SUVmax, Maximum standardized uptake value.
The Journal of Thoracic and Cthose with mixed tumors (n ¼ 97; 2-year DFS, 91.8%;
Figure 1, B) after matching for solid component size.
After matching for SUVmax, therewere 96well-matched
solid and mixed tumor pairs. No significant differences in
clinical characteristics, except for solid component size,
were found between the 2 tumor types (Table 3).
A difference in DFS was identified between patients with
solid tumors (n ¼ 96; 2-year DFS, 87.1%) and those with
mixed tumors (n¼ 96; 2-year DFS, 90.4%; Figure 1, C) af-
ter matching for SUVmax.
After matching for solid component size and SUVmax,
there were 79 well-matched solid and mixed tumor pairs.
No significant differences in clinical characteristics, except
for whole tumor size, were found between the 2 tumor types
(Table 4).
Furthermore, there was no difference in DFS between pa-
tients with solid tumors (n ¼ 79; 2-year DFS, 87.0%) and
patients with mixed tumors (n ¼ 79; 2-year DFS, 83.9%;
Figure 1, D) after matching for solid component size and
SUVmax.
Figure 2 shows examples of solid and mixed tumors with
the same solid component size (1.0 cm). Regardless of tu-
mor type, tumors with low SUVmax were not associated
with lymphatic invasion, whereas those with high SUVmax
were.
DISCUSSION
The present study demonstrated, as expected, that solid
tumors were associated with highly malignant variables,
such as large solid component size, high SUVmax, and lym-
phatic, vascular, and pleural invasion and lymph node me-
tastasis in all cohort patients. In addition, patients with
solid tumors had worse DFS than those with mixed tumors.
A retrospective study has previously shown that pure solid
tumors have malignant potential with nodal or pleural in-
volvement and worse DFS compared with predominantly
solid tumors with a GGO component.13 Other studies
have also revealed that tumors with a predominant GGO
component are less invasive and have a more favorable
prognosis in patients with clinical stage IA lung adenocar-
cinomas.4,8,14 Our study is consistent with these findings.
With regard to the tumor size on HRCT, solid component
size is more useful than whole tumor size for predicting
pathologic invasiveness and prognosis. In our previous
study, solid component size was found to have a higher pre-
dictive value for lymphatic, vascular, and pleural invasion
compared with whole tumor size; furthermore, solid com-
ponent size was an independent prognostic factor for
DFS.6 It was not clear whether mixed tumors and solid tu-
mors have similar malignant behaviors and prognoses when
both have the same solid component size on HRCT. There-
fore, we conducted a matched analysis to compare solid and
mixed tumors after matching for solid component size in
both tumor types. Even after matching for solid componentardiovascular Surgery c Volume 146, Number 1 19
FIGURE 1. DFS curves of patients according to tumor type on HRCT. A, In all cohort patients, 2-year DFS of 94.2% (mean DFS of 47 months; 95%
confidence interval [CI], 46-48 months) and 83.1% (mean DFS of 42 months; 95% CI, 39-45 months) were identified for mixed and solid tumors, respec-
tively (P ¼ .0006). B, In patients matched for solid component size, 2-year DFS of 91.8% (mean DFS of 46 months; 95% CI, 43-48 months) and 83.5%
(mean DFS of 42 months; 95% CI, 38-45 months) were identified for mixed and solid tumors, respectively. C, In patients matched for SUVmax, 2-year
DFS of 90.4% (mean DFS of 42 months; 95% CI, 39-44 months) and 87.1% (mean DFS of 42 months; 95% CI, 38-46 months) were detected for mixed
and solid tumors, respectively. D, In patients matched for solid component size and SUVmax, 2-year DFS of 83.9% (mean DFS of 43 months; 95% CI, 40-
47 months) and 87.0% (mean DFS of 43 months; 95% CI, 40-47 months) were detected for mixed and solid tumors, respectively.
General Thoracic Surgery Tsutani et al
G
T
Ssize in both tumor types on HRCT, solid tumors were more
frequently correlated with high SUVmax and malignant be-
havior compared with mixed tumors. In addition, the DFS
of patients with solid tumors was worse than that of patients
with mixed tumors. This means that solid tumors have more
malignant potential than mixed tumors even if both tumor
types have the same solid component size on HRCT. This
is a new finding. SUVmax on PET/CT is reported to be
a predictor of malignant behavior and prognosis in cases
of lung adenocarcinomas.6,11,12,15-17 SUVmax on PET/CT
is a preoperative factor, whereas lymphatic, vascular, and20 The Journal of Thoracic and Cardiovascular Surgepleural invasion are postoperative factors. We have
previously reported that SUVmax is a significant predictor
of malignant behavior.6,11,12,16,17
We experimentally performed a matched analysis to
compare solid and mixed tumors after matching for SUV-
max. In this matched model, solid tumors and mixed
tumors had similar clinical characteristics except solid
component size, but there seemed to be a difference in
DFS. Although both tumor types have the same SUVmax,
solid tumors seem to have a worse potential than mixed
tumors.ry c July 2013
TABLE 2. Comparison of solid and mixed tumor characteristics in
patients matched for solid component size
Solid tumors
(n ¼ 97)
Mixed tumors
(n ¼ 97) P
Age (y) 64.9  10.4 66.1  10.0 .63
Sex .054
Male 50 (51.5%) 36 (37.1%)
Female 47 (48.5%) 61 (62.9%)
Whole tumor size (cm) 1.8  0.5 2.3  0.5 <.001
Solid component size (cm) 1.8  0.5 1.8  0.5 N/A
SUVmax 4.8  3.4 3.0  2.5 <.001
Lymphatic invasion .008
Negative 63 (64.9%) 81 (83.5%)
Positive 34 (35.1%) 16 (16.5%)
Vascular invasion .029
Negative 62 (63.9%) 76 (78.4%)
Positive 35 (36.1%) 21 (21.6%)
Pleural invasion .003
Negative 71 (73.2%) 88 (90.1%)
Positive 26 (26.8%) 9 (9.9%)
Lymph node metastasis .13
Negative 82 (84.5%) 90 (92.8%)
Positive 15 (15.5%) 7 (7.2%)
Procedure .38
Lobectomy 74 (76.3%) 83 (85.6%)
Segmentectomy 7 (7.2%) 8 (8.2%)
Wedge resection 16 (16.5%) 6 (6.2%)
SUVmax, Maximum standardized uptake value; N/A, not applicable.
TABLE 3. Comparison of solid and mixed tumor characteristics in
patients matched for maximum standardized uptake value
Solid tumor
(n ¼ 96)
Mixed tumor
(n ¼ 96) P
Age (y) 65.4  10.4 65.5  9.3 .94
Sex .26
Male 49 40
Female 47 56
Whole tumor size (cm) 2.0  0.6 2.1  0.6 .24
Solid tumor size (cm) 2.0  0.6 1.5  0.7 <.001
SUVmax 4.0  2.6 4.0  2.6 N/A
Lymphatic invasion .12
Negative 65 74
Positive 31 22
Vascular invasion .47
Negative 62 67
Positive 34 29
Pleural invasion .071
Negative 70 81
Positive 26 15
Lymph node metastasis .54
Negative 80 84
Positive 16 12
Procedure .50
Lobar resection 77 73
Segmentectomy 6 15
Wedge resection 13 8
SUVmax, Maximum standardized uptake value; N/A, not applicable.
TABLE 4. Comparison between solid andmixed tumor characteristics
in patients matched for solid component size and maximum
standardized uptake value
Solid tumor
(n ¼ 79)
Mixed tumor
(n ¼ 79) P
Age (y) 64.4  10.7 66.0  8.9 .27
Sex .62
Male 37 (46.8%) 41 (51.9%)
Female 42 (53.2%) 38 (48.1%)
Whole tumor size (cm) 1.8  0.5 2.2  0.5 <.001
Solid component size (cm) 1.8  0.5 1.8  0.5 N/A
SUVmax 3.7  2.4 3.7  2.6 N/A
Lymphatic invasion .31
Negative 53 (67.1%) 60 (75.9%)
Positive 26 (32.9%) 19 (24.1%)
Vascular invasion 1.0
Negative 56 (70.9%) 56 (70.9%)
Positive 23 (29.1%) 23 (29.1%)
Pleural invasion .71
Negative 62 (78.5%) 65 (82.3%)
Positive 17 (21.5%) 14 (17.7%)
Lymph node metastasis .80
Negative 67 (84.8%) 69 (87.3%)
Positive 12 (15.2%) 10 (12.7%)
Procedure .15
Lobar resection 61 (77.2%) 66 (83.5%)
Segmentectomy 5 (6.3%) 8 (10.1%)
Wedge resection 13 (16.5%) 5 (6.3%)
SUVmax, Maximum standardized uptake value; N/A, not applicable.
Tsutani et al General Thoracic Surgery
The Journal of Thoracic and C
G
T
SIn a next step, we evaluated whether mixed tumors ex-
hibited malignant behavior and prognosis similar to those
of solid tumors after matching for solid component size
and SUVmax. In this matched model, solid tumors and
mixed tumors had similar clinical characteristics and DFS.
As shown in Figure 2, tumors with equivalent solid compo-
nent size and SUVmax had the samemalignant behavior (eg,
lymphatic invasion), regardless of type. The DFS of patients
with solid and mixed tumors was also comparable after
matching for solid component size and SUVmax. These
findings indicate that solid tumors and mixed tumors show
similar biological behavior and prognosis when both have
the same solid component size on HRCTand the same SUV-
max value on PET/CT. In other words, solid component size
onHRCTand SUVmax on PET/CTare important factors for
evaluating malignant behavior of clinical stage IA lung ad-
enocarcinomas before surgery, and this is regardless of the
GGO proportion. Solid and mixed lung adenocarcinoma tu-
mors with low SUVmax reflect pathologic noninvasiveness
andmay be good candidates for sublobar resection.We have
previously reported, in the same population who were eval-
uated in the current study, that tumors with SUVmax less
than 1.5 were not associated with lymph node metastasis
or recurrence,12,18 and we recommend that individuals
with clinical stage IA lung adenocarcinomas withardiovascular Surgery c Volume 146, Number 1 21
FIGURE 2. Examples of solid and mixed tumors on HRCT. A, Whole tumor size ¼ solid component size: 1.0 cm, SUVmax: 1.1. This solid tumor was
negative for lymphatic invasion. B, Whole tumor size¼ solid component size: 1.0 cm, SUVmax: 2.9. This solid tumor was positive for lymphatic invasion.
C, Whole tumor size: 2.8 cm, solid component size: 1.0 cm, SUVmax: 1.1. This mixed tumor was negative for lymphatic invasion. D,Whole tumor size: 2.6
cm, solid component size: 1.0 cm, SUVmax: 2.9. This mixed tumor was positive for lymphatic invasion. SUVmax, Maximum standardized uptake value.
General Thoracic Surgery Tsutani et al
G
T
SSUVmax less than 1.5 should undergo sublobar resection
with adequate surgical margins.18
One of the strengths of this study is the use of PET/CT in
all patients. PET/CT, which is the diagnostic tool of choice
for patients with non–small cell lung cancer, improves the
sensitivity of preoperative staging and reduces the fre-
quency of futile thoracotomies.19 In addition, SUVmax on
PET/CT is a known prognostic factor for non–small cell
lung cancer, especially for adenocarcinoma.6,11,12,16,17 For
patients with clinical stage IA lung adenocarcinoma who
do not undergo PET/CT, tumor type (solid or mixed) is an
important factor for predicting malignant behavior and
prognosis. Because the follow-up period was short in this
study, long-term follow-up is needed to confirm the DFS
results.CONCLUSIONS
In cases of clinical stage IA lung adenocarcinoma, solid
tumors are more malignant than mixed tumors even after22 The Journal of Thoracic and Cardiovascular Surgematching for solid component size in both tumor types.
However, solid tumors have the same malignant potential
and prognosis as mixed tumors when both tumor types are
matched for solid component size on HRCT and SUVmax
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